Published in Cancer Weekly, June 1st, 1998
David Ettinger, M.D., Johns Hopkins Oncology Center, Baltimore, Maryland, and a lead clinical investigator, presented Phase I study results of SunPharm's cancer drug, DENSPM. The results demonstrated that the compound was well tolerated in late stage lung cancer patients refractory to all conventional chemotherapy.
Based on these results, Warner-Lambert initiated multicenter Phase II studies...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.